

Contact: Mark Russo, AngelsShare PR
phone 415.806.4625

HUYA BIOSCIENCE ANNOUNCES STRATEGIC COLLABORATION WITH SANOFI-AVENTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE DRUG DEVELOPMENT CANDIDATES FROM CHINA.

(San Diego, CA. April 6, 2009) HUYA Bioscience International, an innovative leader in developing US/China pharmaceuticals today announces a strategic alliance with a global pharmaceutical company Sanofi-Aventis. The exclusive agreement focuses on sourcing and co-developing novel biopharmaceutical product opportunities originating in China.

HUYA's CEO and President, Dr. Mireille Gingras PhD notes "This strategic partnership with Sanofi-Aventis demonstrates HUYA's growing capability to enable and accelerate worldwide development and commercialization of proprietary preclinical and clinical drug candidates from China. We're extremely excited about working with Sanofi-Aventis, a world leader with a tremendous focus on patients' needs."

According to IMS Health, a leading healthcare market intelligence firm tracking global market dynamics in pharmaceuticals, annual pharmaceutical sales in emerging markets including China is expected to reach \$400bn by 2020, equivalent to current total sales in the US and the five top European markets combined. HUYA is one of the first companies to recognize China's huge potential for meeting the global needs for preclinical and clinical stage compounds in the drug development process. HUYA's business is based on crafting exclusive long term relationships in China and building out a premier network including companies, universities, government research institutions, and bioparks, giving HUYA exclusive access to compounds and biologics in a variety of indications. HUYA identifies and licenses highly promising compounds and HUYA's Chinese partners retain development and marketing rights in China, with the expectation that both parties will benefit from the ensuing research and development. Gingras maintains "HUYA is facilitating the flow of innovative products driving high-value patient treatment options and fueling strong growth for therapeutics originating within China. For companies looking to expand in this market— HUYA can help them quickly identify opportunities in biologic molecules, determine their importance in treatment, and understand the forces underlying

performance – all key to ensuring effective portfolio strategies and maximizing return on investment.”

“This excellent collaboration shows HUYA is becoming a key player in China” declares Marc Cluzel, Executive Vice President, R&D at Sanofi-Aventis. “This partnership will further fuel our product pipeline, allowing us to bring multiple product candidates into the clinic and thereby significantly increasing the chance to give patients access to innovative drugs in several important therapeutic areas. This partnership also aligns with our directive to seek out innovative products, a key growth driver for our company. China represents an amazingly rich and relatively untapped pool of drug candidates, and partnering with HUYA will facilitate the rapid and efficient development of those drugs.”

Dr. Gingras explains one of HUYA’s core strategies is assembling a high level team of scientists and clinical advisors for each new compound. The team collaborates with the Chinese partners to discuss and design clinical trials as the compounds enter the development and approval process in the US, thus speeding the process along and mitigating risk. HUYA’s global team of advisors includes Benedict Lucchesi MD,PhD, Peter Kowey, MD, Dennis Roy, MD, Jefferson Anderson, MD, PhD, Eric J. Topol MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.